Teneobio Announces Achievement of Milestone Payment as Janssen Advances Phase I Study of Bispecific JNJ-75348780 for the Treatment of NHL and CLL
05 avr. 2021 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies,...
Teracero Pharma annonce avoir reçu la première autorisation au Canada en vertu de l'arrêté d’urgence du ministre de la Santé pour un test sérologique rapide pour la COVID-19
17 mars 2021 14h00 HE
|
Teracero Pharma Inc.
Le test NADAL COVID-19 IgG/IgM de nal von Minden GmbH est très sensible et spécifique aux anticorps contre le SRAS-CoV-2, ne nécessite aucune formation particulière et fournit des résultats en 10...
A new stage in COVID-19 testing – Teracero Pharma reports receiving the first authorization for a COVID-19 serology rapid test under the Minister of Health’s Interim Order
17 mars 2021 14h00 HE
|
Teracero Pharma Inc.
nal von Minden GmbH’s NADAL COVID-19 IgG/IgM Test is highly sensitive and specific to antibodies against SARS-CoV-2, requires no special training, and can provide results within 10 minutes MONTREAL,...
Monopar Announces Publication Demonstrating Potential Utility of MNPR-101 as an Imaging Agent to Improve Surgical Outcomes in Bladder Cancer
11 févr. 2021 07h30 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Lee’s Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Breakthrough Therapy Designation in China for the Treatment of Recurrent or Metastatic Cervical Cancer
09 févr. 2021 09h00 HE
|
Sorrento Therapeutics, Inc.
Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lee’s Pharma.China National Medical Products Administration (NMPA) grants breakthrough Therapy...
Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada
09 févr. 2021 07h00 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics...
Precipio Launches COVID-19 Antibody Testing at Point-of-Care
28 janv. 2021 09h30 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that following receipt of an Emergency Use Authorization from the FDA...
Beroni Group’s SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) Received CE Certification
21 déc. 2020 08h30 HE
|
Beroni Group Limited
NEW YORK and SYDNEY, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise focused on the...
Monopar and NorthStar Announce Selection of uPRIT Candidate for Potential Treatment of Severe COVID-19
10 déc. 2020 08h30 HE
|
Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, which are jointly developing a urokinase...
Armanino Volunteers to Join the Fight Against COVID-19 with Antibody Testing System App for New York State
07 déc. 2020 12h02 HE
|
Armanino
SAN RAMON, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Armanino LLP, one of the 25 largest accounting and business consulting firms in the U.S., announced today that it had volunteered to assist the...